Quantification of CD4 responses to combined antiretroviral therapy over 5 years among HIV-infected children in Kinshasa, Democratic Republic of Congo

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 1, 2012, Pages 90-98

  Edmonds, Andrew ^a   Yotebieng, Marcel ^a   Lusiama, Jean ^b   Matumona, Yori ^b   Kitetele, Faustin ^b   Nku, David ^c   Napravnik, Sonia ^a,d   Cole, Stephen R ^a   Van Rie, Annelies ^a   Behets, Frieda ^a,d  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF KINSHASA   (Congo)

^c Salvation Army ^*  (Congo)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral therapy; CD4; Democratic Republic of the Congo; HIV; models; paediatrics; statistical

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CLINICAL ASSESSMENT; CONGO; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; EVIDENCE BASED DENTISTRY; FEMALE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INCIDENCE; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDIATOR; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; PATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CHILD; CHILD, PRESCHOOL; DEMOCRATIC REPUBLIC OF THE CONGO; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; TREATMENT OUTCOME;

EID: 84865724455     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31825bd9b7     Document Type: Article

References (60)

1. Fahey JL, Prince H, Weaver M, et al. Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. Am J Med. 1984;76:95-100.
2. Fauci AS, Macher AM, Longo DL, et al. NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med. 1984;100:92-106.
3. Musoke PM, Mudiope P, Barlow-Mosha LN, et al. Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study. BMC Pediatr. 2010;10:56.
4. Nikolic-Djokic D, Essajee S, Rigaud M, et al. Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline. J Infect Dis. 2002;185:290-298.
5. Soh CH, Oleske JM, Brady MT, et al. Long-term effects of proteaseinhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet. 2003;362:2045-2051.
6. Walker AS, Doerholt K, Sharland M, et al. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS. 2004;18:1915-1924.
7. Ghaffari G, Passalacqua DJ, Caicedo JL, et al. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy. Pediatrics. 2004;114:e604-e611.
8. Ylitalo N, Brogly S, Hughes MD, et al. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Pediatr Adolesc Med. 2006; 160:778-787.
9. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899.
10. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS. 2004;18:1905-1913.
11. George E, Noel F, Bois G, et al. Antiretroviral therapy for HIV-1-infected children in Haiti. J Infect Dis. 2007;195:1411-1418.
12. KIDS-ART-LINC Collaboration. Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa. J Acquir Immune Defic Syndr. 2008;49:523-531.
13. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at: http://aidsinfo.nih.gov/ContentFiles/ PediatricGuidelines.pdf. Accessed August 16, 2010.
14. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children: Recommendations for a Public Health Approach-2010 Revision. Geneva, Switzerland: World Health Organization; 2010.
15. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS. AIDS. 1998;12: F151-F160.
16. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet. 2002;359:733-740.
17. Eley B, Davies MA, Apolles P, et al. Antiretroviral treatment for children. S Afr Med J. 2006;96(9 pt 2):988-993.
18. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007;120: e1134-e1140.
19. Reddi A, Leeper SC, Grobler AC, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13.
20. Nachman SA, Stanley K, Yogev R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA. 2000;283:492-498.
21. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-733.
22. Henry K, Erice A, Tierney C, et al. A randomized, controlled, doubleblind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19: 339-349.
23. De Beaudrap P, Rouet F, Fassinou P, et al. CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2008;49:70-76.
24. Jankelevich S, Mueller BU, Mackall CL, et al. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. J Infect Dis. 2001;183:1116-1120.
25. O'Brien DP, Sauvageot D, Olson D, et al. Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings. Clin Infect Dis. 2007; 44:1245-1248.
26. O'Brien DP, Sauvageot D, Zachariah R, et al. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS. 2006;20:1955-1960.
27. Puthanakit T, Kerr S, Ananworanich J, et al. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J. 2009;28: 488-492.
28. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41:100-107.
29. Rosenblatt HM, Stanley KE, Song LY, et al. Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection. J Infect Dis. 2005;192:445-455.
30. Sleasman JW, Nelson RP, Goodenow MM, et al. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. J Pediatr. 1999;134: 597-606.
31. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999;341: 1874-1881.
32. van Rossum AM, Scherpbier HJ, van Lochem EG, et al. Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS. 2001;15:2267-2275.
33. Chiappini E, Galli L, Tovo PA, et al. Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. BMC Infect Dis. 2009;9:140.
34. Newell ML, Patel D, Goetghebuer T, et al. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation? J Infect Dis. 2006;193:954-962.
35. Resino S, Resino R, Micheloud D, et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis. 2006;42: 862-869.
36. Weinberg A, Dickover R, Britto P, et al. Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS. 2008;22:2267-2277.
37. + cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis. 2008;46:1751-1760.
38. Hansudewechakul R, Sirisanthana V, Kurniati N, et al. Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia pediatric HIV observational database. J Acquir Immune Defic Syndr. 2010;55: 503-509.
39. WHO, UNAIDS, and UNICEF. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2010. Geneva, Switzerland: World Health Organization; 2010.
40. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2010.
41. De Baets AJ, Bulterys M, Abrams EJ, et al. Care and treatment of HIVinfected children in Africa: issues and challenges at the district hospital level. Pediatr Infect Dis J. 2007;26:163-173.
42. De Baets AJ, Ramet J, Msellati P, et al. The unique features of pediatric HIV-1 in sub-Saharan Africa. Curr HIV Res. 2008;6:351-362.
43. Edmonds A, Lusiama J, Napravnik S, et al. Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children. Int J Epidemiol. 2009;38:1612-1621.
44. Edmonds A, Yotebieng M, Lusiama J, et al. The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. PLoS Med. 2011;8:e1001044.
45. Ciaranello AL, Chang Y, Margulis AV, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009;49:1915-1927.
46. Ananworanich J, Puthanakit T, Saphonn V, et al. Lessons from a multicentre paediatric HIV trial. Lancet. 2008;372:356-357.
47. Verweel G, Saavedra-Lozano J, van Rossum AM, et al. Initiating highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children in Europe and the United States: comparing clinical practice to guidelines and literature evidence. Pediatr Infect Dis J. 2006; 25:987-994.
48. Welch SB, Gibb D. When should children with HIV infection be started on antiretroviral therapy? PLoS Med. 2008;5:e73.
49. Cole SR, Hernan MA, Margolick JB, et al. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol. 2005;162:471-478.
50. Patel K, Hernan MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis. 2008;46:507-515.
51. National Program for the Fight against AIDS. National Guide for Antiretroviral Treatment of HIV Infection. Kinshasa, Democratic Republic of the Congo: Ministry of Health; 2005.
52. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach-2006 Rev. Geneva, Switzerland: World Health Organization; 2006.
53. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2006.
54. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach-2010 Rev. Geneva, Switzerland: World Health Organization; 2010.
55. Petersen ML, Wang Y, van der Laan MJ, et al. Assessing the effectiveness of antiretroviral adherence interventions. Using marginal structural models to replicate the findings of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(suppl 1):S96-S103.
56. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10:37-48.
57. + lymphocyte counts in healthy children born to human immunodeficiency virus 1-infected parents. Military Pediatric HIV Consortium. Pediatr Infect Dis J. 1994;13:70-72.
58. Pintilie M. Competing risks: A Practical Perspective. Chichester, England: John Wiley & Sons; 2006.
59. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med. 1993;12:737-751.
60. Hernan MA, McAdams M, McGrath N, et al. Observation plans in longitudinal studies with time-varying treatments. Stat Methods Med Res. 2009;18:27-52.